CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...